poloxalene has been researched along with pilocarpine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blanchard, J; Desai, SD | 1 |
| Chen, B; Chen, S; Chen, Z; Fang, Z; Li, Z; Ni, G; Ning, Y; Qin, J; Wu, C; Zhou, J; Zhou, L | 1 |
2 other study(ies) available for poloxalene and pilocarpine
| Article | Year |
|---|---|
In vitro evaluation of pluronic F127-based controlled-release ocular delivery systems for pilocarpine.
Topics: Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Delivery Systems; Excipients; Hypromellose Derivatives; Least-Squares Analysis; Methylcellulose; Miotics; Ophthalmic Solutions; Pilocarpine; Poloxalene; Polyethylene Glycols; Povidone; Rheology; Viscosity | 1998 |
Pluronic P85-coated poly(butylcyanoacrylate) nanoparticles overcome phenytoin resistance in P-glycoprotein overexpressing rats with lithium-pilocarpine-induced chronic temporal lobe epilepsy.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chronic Disease; Disease Models, Animal; Drug Resistance; Enbucrilate; Epilepsy, Temporal Lobe; Female; Hippocampus; Lithium; Nanoparticles; Phenytoin; Pilocarpine; Poloxalene; Rats, Sprague-Dawley; Reproducibility of Results; Seizures; Tissue Distribution | 2016 |